Bioavailability and Bioequivalence Study of Ziftomenib in Participants With Relapsed/Refractory AML or MDS
Key facts
- Where
- Barcelona, Madrid, Oviedo, Sevilla és Valencia, SpanyolországSee the 5 sites
- Phase
- 1. fázis
Where in Spanyolország
- Hospital Clinic de BarcelonaBarcelona, SpanyolországToborzás még nem indult
- MD Anderson Cancer CenterMadrid, SpanyolországToborzás még nem indult
- Hospital Universitario Central De AsturiasOviedo, SpanyolországToborzás még nem indult
- University Hospital Virgen Del Rocio S.L.Sevilla, SpanyolországToborzás még nem indult
- Hospital Universitario Y Politecnico La FeValencia, SpanyolországToborzás még nem indult
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Kura Oncology, Inc.
- Trial code
- NCT07929740EU 2025-524332-19-00
- Record updated
- 2026. november 10.
- Original description
This study will evaluate the pharmacokinetics (PK) of ziftomenib drug products to inform relative bioavailability (rBA) and bioequivalence (BE) assessments.Read full original descriptionShow less
Relative Bioavailability and Bioequivalence Study of Ziftomenib Drug Products in Participants With Relapsed/Refractory AML With NPM1 Mutation, or With Relapsed/Refractory AML or MDS With Mutations Associated With MEIS1 Overexpression
This study will evaluate the pharmacokinetics (PK) of ziftomenib drug products to inform relative bioavailability (rBA) and bioequivalence (BE) assessments.
Inclusion: Age ≥18 years; Relapsed/refractory NPM1-mutated AML, or relapsed/refractory AML or MDS with a mutation associated with MEIS1 overexpression; disease confirmed in blood and/or bone marrow, as applicable, and not a candidate for currently approved standard-of-care regimens or hematopoietic stem cell transplantation (HSCT); Female participants must not be pregnant or breastfeeding; Male participants with partners of childbearing potential must agree to abstinence or highly effective contraception and refrain from sperm donation during treatment and for at least 90 days after the last dose; Signed informed consent; Eastern Cooperative Oncology Group (ECOG) performance status ≤2 and life expectancy ≥2 months; Adequate organ function: estimated glomerular filtration rate ≥30 mL/min/1.73 m²; bilirubin ≤1.5 × the upper limit of normal (ULN), unless attributable to Gilbert's syndrome or leukemic disease; and AST and ALT ≤3 × ULN; Peripheral white blood cell count ≤25,000/µL before Day 1 of Part 1; hydroxyurea or cytarabine may be used to control the count.
Exclusion: Clinically active central nervous system (CNS) leukemia; participants with controlled CNS leukemia receiving intrathecal therapy at study entry may be eligible; Grade ≥2 acute graft-versus-host disease (GVHD), moderate/severe limited chronic GVHD, or extensive chronic GVHD; Active HIV, hepatitis C, or hepatitis B infection, as defined in the protocol; participants with controlled disease are not excluded; Active, uncontrolled systemic fungal, bacterial, viral, or other infection; Significant cardiovascular disease, including unstable angina, uncontrolled hypertension or arrhythmia, qualifying heart failure, ischemic or severe valvular heart disease, or stroke, transient ischemic attack, or myocardial infarction within the preceding 6 months; Mean QT interval corrected using Fridericia's formula (QTcF) >480 ms on triplicate electrocardiograms obtained within 5 minutes of each other; The full inclusion and exclusion criteria, including applicable definitions are presented in the study protocol.